

Tenapanor Has Early Onset of Action in Treating Symptoms of Irritable Bowel Syndrome With Constipation (T3MPO-1 and T3MPO-2 Trials)

Ron Fogel,¹ Susan Edelstein,² Suling Zhao,² Yang Yang,² David P. Rosenbaum²

¹Digestive Health Center of Michigan, Chesterfield, MI, USA; ²Ardelyx, Inc., Waltham, MA, USA


Background

- Tenapanor is a first-in-class, minimally systemic, small-molecule inhibitor of intestinal sodium-hydrogen exchanger isoform 3 (NHE3) that inhibits dietary sodium absorption, resulting in increased stool water content.^{1,2}
- Tenapanor is approved for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) based on results from 2 phase 3 randomized clinical trials (T3MPO-1 [NCT02621892] and T3MPO-2 [NCT02686138]).³⁻⁵
- In the T3MPO-1 and T3MPO-2 clinical trials, tenapanor effectively improved IBS-C symptoms with acceptable safety and tolerability over 12 and 26 weeks, respectively.^{3,4}
 - In the primary analyses, significantly more patients treated with tenapanor experienced a combined response rate, defined as a ≥30% reduction in average weekly worst abdominal pain and an increase of ≥1 average weekly complete spontaneous bowel movement (CSBM) from baseline for ≥6 of 12 weeks compared with placebo. Tenapanor-treated patients also experienced significant improvements in other abdominal symptoms, as well as global irritable bowel syndrome (IBS) symptoms.^{3,4}
 - Diarrhea was the most commonly reported adverse event with tenapanor; in both studies, 6.5% of tenapanor-treated patients discontinued study drug due to diarrhea vs 0.7% with placebo.^{3,4}
- To evaluate the onset of action for tenapanor, we investigated the efficacy of tenapanor within the first week of treatment in the T3MPO-1 and T3MPO-2 studies.

Methods

- T3MPO-1 and T3MPO-2 were phase 3, randomized, double-blind, placebo-controlled trials (**Figure 1**).
 - Full details of the study designs were previously reported.^{3,4}
- After a 2-week screening period, patients were randomized to tenapanor 50 mg twice a day or placebo twice a day for 12- and 26-week treatment periods in T3MPO-1 and T3MPO-2, respectively.
- Patients self-reported information about the status of their IBS symptoms daily using an interactive voice response system (IVRS) diary accessed by a touch-tone telephone (**Box**).
- To evaluate the early response to treatment, we investigated the proportion of responders within the first week of treatment for overall response, CSBM response, and abdominal symptom (pain, discomfort, and bloating) responses.
 - An overall response consisted of both an abdominal pain and a CSBM response in the same week.
 - Abdominal pain response was defined as a reduction of ≥30% in average weekly worst abdominal pain score from baseline.
 - CSBM response was defined as an increase of ≥1 in the average weekly CSBM frequency from baseline.
 - Responses for abdominal discomfort and abdominal bloating were defined as a reduction of ≥30% from baseline in average weekly abdominal discomfort or abdominal bloating score, respectively.
- We examined the average weekly abdominal pain score, average weekly CSBM frequency, and average weekly spontaneous bowel movement (SBM) frequency as additional measures of efficacy in the first week of treatment.
- All analyses were performed on the intent-to-treat (ITT) population, which included all patients who met the study eligibility criteria, were randomized, and received ≥1 dose of study drug.

Figure 1. T3MPO-1 and T3MPO-2 Study Design



Box. Interactive Voice Response System (IVRS) Diary

The IVRS diary collected information on daily stool frequency, stool consistency, straining, abdominal pain, abdominal discomfort, abdominal bloating, abdominal fullness, abdominal cramping, and rescue medication usage. IBS severity and constipation severity were assessed weekly through the IVRS diary.^a Example questions:^b

- How would you rate your worst abdominal pain over the past 24 hours? ...your abdominal discomfort over the past 24 hours? ...your abdominal bloating over the past 24 hours?* Each assessed on a scale of 1 (none) to 10 (very severe)
- How many bowel movements have you had in the past 24 hours?* For each bowel movement:
 - Please enter the time of the bowel movement using the 12 hours AM/PM format and indicate if it occurred today or yesterday.*
 - Did you feel like you completely emptied your bowels?* Yes/No

^aEntries into the IVRS diary must have been recorded between 6:00 PM and 11:59 PM (local time). ^bSample questions reflect questions relevant to the analysis presented. The full IVRS diary included 4 weekly questions and 7 daily questions (with sub-questions for each bowel movement and each use of rescue medication). IBS, irritable bowel syndrome; IVRS, interactive voice response system.

Results

Patients

- Demographics and baseline characteristics were well balanced between the tenapanor and placebo groups in both T3MPO-1 and T3MPO-2.^{3,4}

Week 1 response

- For week 1, the tenapanor group had a significantly higher overall responder rate than the placebo group. Significantly higher CSBM and abdominal symptom responder rates were also observed in the tenapanor arm (**Figure 2**).


Week 1 change in abdominal pain score

- From baseline to week 1, the average weekly abdominal pain score decreased (**Figure 3**). The maximum mean percent decreases with tenapanor treatment were 44.3% and 54.1% over the 12 weeks of T3MPO-1 and 26 weeks of T3MPO-2, respectively (vs 31.0% and 42.0%, respectively, with placebo).

Week 1 change in bowel movement frequency

- The average weekly CSBM frequency increased from baseline to week 1 (**Figure 4**). Maximum mean increases in the average weekly CSBM frequency with tenapanor treatment were 2.3 and 3.5 over the 12-week T3MPO-1 and 26-week T3MPO-2 studies, respectively (vs 1.2 and 1.6, respectively, with placebo).
- The average weekly SBM frequency increased from baseline to week 1, with significant improvements with tenapanor compared with placebo in both studies (**Figure 5**).

Figure 2. Responder Rates for Week 1 in T3MPO-1 and T3MPO-2



Conclusions

- Tenapanor provided statistically significant and clinically meaningful improvements in gastrointestinal and pain symptoms compared with placebo in as early as the first week of treatment.
 - Within the first week of tenapanor treatment, approximately 40% of patients had a CSBM response (an increase of ≥1 in average weekly CSBM frequency), and approximately 20% of patients achieved a response to abdominal symptoms of pain, bloating, or discomfort (≥30% reduction in average weekly abdominal symptom score).
- Building on the overall findings from the T3MPO-1 and T3MPO-2 studies,^{3,4} these data support tenapanor as a clinically meaningful treatment option for patients with IBS-C that provides symptom relief as soon as the first week of treatment in some patients.

Disclosures

Ron Fogel has no relationships to disclose. Susan Edelstein, Suling Zhao, Yang Yang, and David P. Rosenbaum are employees of Ardelyx, Inc.

Acknowledgments

Medical writing support for the development of this poster, under the direction of the authors, was provided by Ashfield MedComms, an Ashfield Health company, and funded by Ardelyx, Inc.

References

- Spencer AG et al. *Sci Transl Med*. 2014;6(27):227ra36.
- Johansson S et al. *Clin Exp Nephrol*. 2017;21:407-16.
- Chey WD et al. *Am J Gastroenterol*. 2020;115:281-93.
- Chey WD et al. *Am J Gastroenterol*. 2021;116:1294-303.
- IBSRELA (tenapanor hydrochloride) [prescribing information]. Waltham, MA: Ardelyx, Inc.; 2021.

Figure 3. Weekly Abdominal Pain Scores From T3MPO-1 and T3MPO-2




Figure 4. Average Weekly CSBM Frequency in T3MPO-1 and T3MPO-2




Figure 5. Change From Baseline in Average Weekly SBM Frequency During Week 1

